A National Registry of Multiple Sclerosis (MS) – Multiple Sclerosis Research and Registry Network in India and Allied Registry (IMSRN) – has been established by the Research Council Indian Medicine (ICMR) on June 11, 2022, and it is the first agency in the nation to research a dedicated database of MS and allied demyelinating disorders. Balram Bhargava, ICMR Director General, said: “There is a need for insight into patient disease profiles and outcomes as well as research planning in different areas of pathophysiology, etiology, management and rehabilitation of these disorders”.
Using new therapies for multiple sclerosis
Balram Bhargava has said that there are new, approved drugs called ‘disease-modifying therapies’ that are considered effective, among them, autologous hematopoietic bone marrow transplantation as a treatment advancement. MS in select cases.
MS is a neurological disorder that usually affects young people between the ages of 20 and 40, but can also occur in children and adolescents.
‘Multiple sclerosis is a neurological disorder that usually affects young people aged 20 to 40, but can also occur in children and adolescents. “
Women are affected by this disease more than men. It is estimated that MS affects about 20 people per ten thousand of the population and neuromyelitisoptica spectrum disorder (NMOSD) affects about 2.7 per ten thousand of the population although this is likely an underestimate.
The registry will create an organized system for collecting, storing, retrieving, analyzing, managing and resulting data. IMSRN was started in October 2021, with AIIMS Delhi as the national coordination center and 24 participating centers spread across the country.
Advertisement
Speaking about the process, RS Dhaliwal, head of non-communicable diseases, ICMR added that as of now, more than 1,000 patients have been recruited to this registry.
The registry will pave the way for bringing together experts to generate ideas and research proposals that focus on pathophysiology, etiology and imaging, he stressed.
Source: IANS
Advertisement
